The dimer interface of ERK1/2 provides a potential strategy for selective inhibition of pathological cardiac hypertrophy

被引：0
|
作者：
Tomasovic, A. [1 ]
Kramer, S. [1 ]
Huemmert, M. [1 ]
Katus, Ha [2 ]
Mueller, O. [2 ]
Lorenz, K. [3 ]
机构：
[1] Univ Wurzburg, Inst Pharmacol & Toxicol, Wurzburg, Germany
[2] Univ Hosp Heidelberg, Internal Med 3, Heidelberg, Germany
[3] Leibniz Inst Analyt Sci ISAS, Dortmund, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
810
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [31] Inhibition of ERK1/2 by silymarin in mouse mesangial cells
    Youn, Cha Kyung
    Cho, Sung Il
    Lee, Min Young
    Jeon, Young Jin
    Lee, Seog Ki
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (01): : 117 - 124
  • [32] Sulfenylation of ERK1/2: A novel mechanism for SO2-mediated inhibition of cardiac fibroblast proliferation
    Ge, Mei
    Zhang, Lulu
    Du, Junbao
    Jin, Hongfang
    Lv, Boyang
    Huang, Yaqian
    HELIYON, 2024, 10 (14)
  • [33] Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases
    Gozdz, Agata
    Vashishta, Aruna
    Kalita, Katarzyna
    Szatmari, Erzsebet
    Zheng, Jing-Juan
    Tamiya, Shigeo
    Delamere, Nicholas A.
    Hetman, Michal
    JOURNAL OF NEUROCHEMISTRY, 2008, 106 (05) : 2056 - 2067
  • [34] AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway
    Meng, Rongsen
    Pei, Zhaohui
    Zhang, Aixia
    Zhou, Yutian
    Cai, Xingming
    Chen, Baolin
    Liu, Guanjie
    Mai, Weiyi
    Wei, Jianrui
    Dong, Yugang
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2011, 511 (1-2) : 1 - 7
  • [35] Reversal of pathological cardiac hypertrophy via the MEF2-coregulator interface
    Wei, Jianqin
    Joshi, Shaurya
    Speransky, Svetlana
    Crowley, Christopher
    Jayathilaka, Nimanthi
    Lei, Xiao
    Wu, Yongqing
    Gai, David
    Jain, Sumit
    Hoosien, Michael
    Gao, Yan
    Chen, Lin
    Bishopric, Nanette H.
    JCI INSIGHT, 2017, 2 (17):
  • [36] BRAF INHIBITORS, SB590885 AND DABRAFENIB, ENHANCE ERK1/2 SIGNALLING IN CARDIOMYOCYTES AND PROMOTE CARDIAC HYPERTROPHY
    Meijles, Daniel
    Hardyman, Michelle
    Rostron, Kerry
    Fuller, Stephen
    Sugden, Peter
    Clerk, Angela
    HEART, 2017, 103 : A146 - A147
  • [37] Adiponectin Upregulates MiR-133a in Cardiac Hypertrophy through AMPK Activation and Reduced ERK1/2 Phosphorylation
    Li, Ying
    Cai, Xiaojun
    Guan, Yuqing
    Wang, Lei
    Wang, Shuya
    Li, Yueyan
    Fu, Ying
    Gao, Xiaoyuan
    Su, Guohai
    PLOS ONE, 2016, 11 (02):
  • [38] Songling Xuemaikang Capsule inhibits isoproterenol-induced cardiac hypertrophy via CaMKIIδ and ERK1/2 pathways
    Qi, Jianyong
    Tan, Yafang
    Fan, Dancai
    Pan, Wenjun
    Yu, Juan
    Xu, Wen
    Wu, Jiashin
    Zhang, Minzhou
    JOURNAL OF ETHNOPHARMACOLOGY, 2020, 253
  • [39] A cardio-safe peptide-based targeting strategy protects from pathological ERK1/2 signalling
    Brand, T.
    Schanbacher, C.
    Tomasovic, A.
    Kramer, S.
    Huemmert, M.
    Mueller, O.
    Dobrev, D.
    El-Armouche, A.
    Cuello, F.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) : 14 - 14
  • [40] MURC Promotes Recruitment of Erk1/2 to Caveolae of the Plasma Membrane and Concentric Cardiac Hypertrophy Induced by a1-adrenergic Stimulation
    Ogata, Takehiro
    Nakanishi, Naohiko
    Miyagawa, Kotaro
    Hamaoka, Tetsuro
    Maruyama, Naoki
    Ueyama, Tomomi
    CIRCULATION, 2013, 128 (22)
12345